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quantitative analyses of LH-RH-like membrane receptors were performed in five tumors from the 
tr~splan~ble Dunning R3372H rat prostatic adenoc~~inom~, The binding of ~-Trpb-LH-RH, an agonist 
of LH-RN, was observed in al1 5 tumors. The antagonist [Ac”~p-Cl-Phei,2,~-Trp3,D-Lys6,D-Ala’*]-LH- 
RH was bound to 4 tumors. The apparent equilibrium dissociation constant (&I) for D-Trp’-LH-RH 
receptor was from 2.6-3.9 x lo-‘* M, The apparent eq~ilihrium Bmax values (rn~~urn comber of 
binding sites) were from 17.2-86.0 fmol/mg membrane protein for D-Trp6-LH-RH receptor. The & for 
the antagonist was from 2.4-2.7 x lo-” M and the B max values were from 35.5-66.0 fmoi/mg membrane 
protein. Similar binding studies performed in 6 normal rat prostates showed no binding capacities. 
I)unning R3327fi prostate tumor Membrane protein LH-RH analog binding 
We have observed an inhibition of the growth of 
Dunning R3327H prostate tumor after treatment 
with agonistic ]l] as well as antagonistic [2] 
analogs of LH-RH. Although prostate tissue is not 
normally a target tissue for LH-RH action, we 
have found LH-RH-like receptors on plasma mem- 
branes from Dunning R3327N prostate tumor, 
which bind agonistic as well as antagonistic 
analogs of LH-RH. The present report describes 
our findings. 
2. MATERIALS AND METHODS 
[A~-Dp-Cl~Phe1,2,D-Trp~,D-Lys6-D-Ala~o]-LH- 
RH, an antagonistic analog of LH-RH, was syn- 
thesized in our laboratory by solid-phase methods 
[3]. D-Trp6-LH~RH was also synthesized by solid- 
phase methods and supplied by Debiopharm SA 
(Lausanne), 
2.1. Tissue prepurfftion 
Normal (Male Copenhagen x Fisher)Fi rats and 
rats bearing the ~drogen-dependent, well- 
differentiated R3327H Dunning rat adenocar- 
cinema were kindly provided by Norman Altman 
~apa~colaou Cancer Research Institute, Miami 
FL), Tumors were palpable 160 days after 
transplantation, and rats bearing tumors 
3 25 mm3 were selected for the study. Rats were 
decapitated and the ventral and dorsal prostates or 
prostate tumors rapidly removed, cleaned of 
necrotic or connective tissue, washed with 0.25 M 
sucrose and placed on ice. In some cases normal 
pituitary tissue was removed to compare the bind- 
ing ability of the pituitary membranes and the pro- 
state tumor membranes. Tissues were frozen and 
kept at - 70°C until assayed for L-H-RH receptors. 
2.2. Membrane preparation 
The tissue was homogenized with Dounce 
homogenizer at 4°C in assay buffer consisting of 
10 mM Tris-HCl (pH 7.4), 1 mM DTT, 0.1% 
BSA and centrifuged for 10 min at 1000 x g. The 
supernatant was then centrifuged for 20 min at 
20000 x g. The pellet was suspended in assay buf- 
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fer, centrifuged again as above and resuspended in 
buffer. The presence of plasma membranes in this 
fraction was assessed by the distribution of 
enzymic activities: adenylate cyclase [4], 
5 ’ -nucleotidase [5] and phosphodiesterase [6]. 
2.3. Iodination of LH-RH analogs 
[D-Trp6]-LH-RH and [Ac-Dp-Cl-Phe”‘,D- 
Trp3,D-Ly?,D-Ala”]-LH-RH were iodinated by a 
solid phase method with iodogen [7]. The reaction 
mixture was applied on a Sephadex SP-C25 col- 
umn (2 x 1 cm) equilibrated to pH 3.0 with 
0.01 mol/glycine-HCl buffer. The same buffer 
was then used to elute unreacted iodide. The pep- 
tide peak was eluted with 0.5 mol/l phosphate buf- 
fer (pH 7.5). The labeled peptide fraction was 
rechromatographed if necessary on Sephadex 
G-25. The specific activity of the iodinated 
analogs, measured by self-displacement in the 
radioreceptor assay, was 1000-1290 pCi/pg for 
the agonist and SSO-lOSO,&i/pg for the ant- 
agonist. The maximum binding of labeled analogs 
was estimated by using an excess of rat pituitary 
membranes and comparing the maximum binding 
of these radioligands to that observed in mem- 
branes from Dunning R3327H prostate tumor. 
The maximum binding of labeled analogs was 
60-65% of counts added for both analogs. Recep- 
tor affinity and binding capacity were expressed as 
fmol analog bound/mg membrane protein. 
2.4. Binding assays 
The assays were conducted in triplicate in BSA- 
precoated polypropylene tubes. The incubation 
mixture contained assay buffer (10 mM Tris-HCI 
(pH 7.4), 1 mM DTT and 0.5% BSA), the 1251- 
labeled agonist or antagonist of LH-RH 
-50000 cpm, varying amounts of unlabeled 
analogs, and 75-2OOpg membrane protein in 
0.3 ml final vol. The tubes were incubated for 
90 min at 4°C. The reaction was stopped by ad- 
ding 1 ml ice-cold assay buffer, and the receptor- 
bound ligand was separated from the unbound by 
filtration under vacuum through Whatman GF/C 
filter. Of the added tracer, -8% was bound in the 
absence of unlabeled hormone. The non- 
displaceable binding, estimated in the presence of 
80 ng unlabeled analog, was < 2% of the total 
counts added. 
2.5. Protein measurement 
Protein was determined following [8] as 
modified [9]. Protein samples were analyzed at 3 
dilutions in duplicate. 
3. RESULTS 
3.1. Optimal concentration of membrane proteins 
Optimal concentration of membrane proteins by 
radioreceptor assay is shown in fig.1. The points 
represent he mean of duplicates. A linear relation- 
ship was observed between the amount of par- 
ticulate protein (up to 150 pg) and the specifically- 
bound radioactivity (with 0.9 pmol tested LH-RH 
analogs). 
3.2. Characterization of LH-RH-like receptor in 
Dunning R3327H rat prostate tumor 
The specific binding of LH-RH analogs to mem- 
brane proteins was maximal at 4”C, and steady 
state binding was reached at 90 min and remained 
stable for an additional 80 min. When the 
temperature was increased to 20, 25 or 37”C, the 
association rate was increased but the maximum 
binding was reduced. 
After establishing optimal conditions for the 
radioreceptor assay, the binding inhibition curves 
[lo] were performed. An initial low concentration 
of “‘1-D-Trp6-LH-RH (15 fmol/tube) and in- 
creasing amounts of both labeled and unlabeled 
agonist gave similar half-maximal displacements 
(150 fmol/tube for labeled analog and 
100 fmol/tube for unlabeled analog). The data 
from inhibition curves were analyzed by Scatchard 
plot and gave & = 3 X lo- lo M for labeled analog, 
251 
Fig.1. Specific binding of ‘251-D-Trp6-LH-RH to 
increased concentration of membrane proteins from 
Dunning R3327H prostate tumors. 
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and 2.5 x lo-” M for unlabeled analog. Similar 
results have been obtained with the antagonist. 
The characterization of the LH-RH-like recep- 
tor in Dunning R3327H prostate tumor was per- 
formed in two kinds of experiments with un- 
saturated amounts of membrane protein: 
(1) Varying amount of cold analog/tube 
(12.5-640 pg for agonist and 13.5-685 pg for 
antagonist, with constant amount of 1251 
analog/ 10 pg); 
(2) Varying amounts of ‘2SI-labeled analog Fig.2. Scatchard plots of ‘251-D-Trp6-LH-RH ( w-+) 
(23-312 pg for agonist and 23-347 pg for and ‘251-[Ac-Dp-Cl-Phe1*2 ,D-Trp3,D-Ly#,D-Ala”]- 
antagonist). LH-RH (M) with Dunning R3327H prostate tumor 
membrane proteins. In all these experiments 75 pg and 150 ,ug mem- 
brane protein/tube were used. Scatchard plot 
analyses of these two kinds of experiments gave 
similar values for equilibrium dissociation con- 
stant and B,, (fig.2). Subsequent determinations 
of binding capacities for agonist and antagonist 
were performed by using saturation analysis. 
Fig.3 represents the saturation curve of specific 
binding (difference between the total and 
nonspecific binding) for each point of the curve. 
The inset Scatchard plot from saturation curves 
showed that the dissociation constants and the 
Table 1 





&fsD Capacity in fmol/mg membrane &kSD Capacity in fmol/mg membrane 
(lo-” M) protein (lo-” M) protein 
Scatchard Saturation Scatchard Saturation 










Tumor 1 1 2.6 f 0.3 
n= 9 
Tumor 2 1 3.9 f 0.3 
n= 7 
Tumor 3 1 2.98 + 0.2 
n= 5 
Tumor 4 1 2.8 f 0.3 
n= 5 
Tumor 5 1 3.0 * 0.3 





2.4 + 0.28 
n=8 
3.2 f 0.3 
n=7 






74.0 64.8 2.7 f 0.25 60.5 53.9 
n=8 
n = Number of points in the Scatchard plot used 
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Fig.3. Saturation curves of LH-RH agonist (ti) and 
antagonist ( i) binding to prostate tumor membrane 
proteins. Inset: Scatchard plot from both saturation 
curves, (D--+) agonist and (M) antagonist. 
Table 2 
Lack of effect of TRH and somatostatin o  binding of 
LH-RH analogs (fmol/mg membrane protein) from 
Dunning R3327H prostate tumor 
[Peptide] Agonist p Antagonist p 
WI (Means f SE) (Means f SE) 
TRH 82.5 f 0.5 66.5 f 0.45 
1o-8 82.1 + 0.44 NS 65.8 f 0.5 NS 





81.8 f 0.65 NS 65.8 f 0.48 NS 
82.4 -t 0.75 NS 66.7 f 0.56 NS 
The binding was determined as in section 2. The data 
presented here are means f SE of triplicate incubations 
with 960 fmol/tube for agonist or antagonist of LH-RH 
with 2OOpg membrane protein. Differences between 
means were analyzed by Student’s t-test or one-way 
analysis of variance with Duncan’s multiple range test 
binding capacity calculated from saturation 
analysis were in good agreement with binding 
capacities calculated from Scatchard plots (table 
1). The binding of LH-RH analogs to membrane 
proteins from prostate tumors was not affected by 
TRH and somatostatin (table 2). 
4. DISCUSSION 
Our previous observations that administration 
of agonistic and antagonistic analogs of LH-RH 
induced regression of rat prostate tumors were 
probably linked to the inhibitory effect of LH-RH 
on the levels of sex steroids [1,2]. Others have 
demonstrated a direct action of agonistic LH-RH 
analogs on testes and ovaries, and the presence of 
LH-RH receptors in these tissues [I l-171. The pre- 
sent work indicates that Dunning R3327H tumor 
tissue possesses binding capabilities for both LH- 
RH agonist and antagonist. Normal prostate tissue 
did not bind these LH-RH analogs. The binding of 
LH-RH antagonist to prostate tumor tissue 
demonstrates an extrapituitary effect of ant- 
agonistic analogs of LH-RH. To characterize the 
LH-RH-like receptor we used Scatchard plot 
analysis with unsaturated amounts of membrane 
proteins and a saturation curve analysis. The max- 
imum binding capacities in both sets of ex- 
periments were similar for agonist (86 fmol/mg 
protein vs 82.5 fmol/mg protein), and for an- 
tagonist (66 fmol/mg protein vs 66.5 fmol/mg 
protein). The LH-RH-like receptor in Dunning 
R3327H rat prostate tumor is a single class recep- 
tor with Kd 2.6-3.9 x lo-” M for agonist and 
2.4-2.7 x lo-” M for the antagonist. An ap- 
parent absence of high affinity binding sites in 
prostatic tissue of normal rats in our assay suggests 
that carcinogenic transformation induces changes 
in membrane structure and composition, resulting 
in the appearance of LH-RH-like binding sites. 
Which components of the ectopic LH-RH-like 
receptor are responsible for the binding of LH-RH 
analogs in Dunning R3327H prostate tumor, and 
whether prostate tumor receptors are similar in 
structure and composition to those of the 
pituitary, is under investigation. 
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